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Abstract
Wilms tumour is a childhood tumour that arises as a consequence of somatic and rare germ-
line mutations, the characterisation of which has refined our understanding of nephrogen-
esis and carcinogenesis. Here we report that germline loss of function mutations in TRIM28
predispose children to Wilms tumour. Loss of function of this transcriptional co-repressor,
which has a role in nephrogenesis, has not previously been associated with cancer. Inacti-
vation of TRIM28, either germline or somatic, occurred through inactivating mutations, loss
of heterozygosity or epigenetic silencing. TRIM28-mutated tumours had a monomorphic
epithelial histology that is uncommon for Wilms tumour. Critically, these tumours were nega-
tive for TRIM28 immunohistochemical staining whereas the epithelial component in normal
tissue and other Wilms tumours stained positively. These data, together with a characteristic
gene expression profile, suggest that inactivation of TRIM28 provides the molecular basis
for defining a previously described subtype of Wilms tumour, that has early age of onset and
excellent prognosis.
Author summary
The germline and somatic molecular events associated with Wilms tumour, a childhood
kidney cancer, have been progressively defined over the past three decades. Among the
uncharacterised tumours are a group of tumours that have monomorphic epithelial histol-
ogy, familial association, distinctively clustered gene-expression patterns, early age of
diagnosis, and excellent prognosis. Here, we describe germline mutations and loss of func-
tion of TRIM28 in familial Wilms tumours, along with somatic loss of function in a non-
familial Wilms tumour. All TRIM28-mutant tumours showed the rare monomorphic epi-
thelial histology, suggesting that loss of TRIM28 expression could be a useful marker to
define a group of tumours with excellent prognosis. Future studies could lead to
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Introduction
The study of Wilms tumour, a rare childhood kidney tumour [1], has facilitated the discovery of
mechanisms of organogenesis and the neoplastic transformation of embryonic tissue. First, the
discovery of inactivating mutations and deletions of WT1 in Wilms tumours [2] led to the revela-
tion of its key roles in development of numerous embryonic tissues [3, 4]. Similarly, activating
mutations of CTNNB1 in Wilms tumours highlighted the importance of WNT pathway activation
in renal development and in multiple tumour types [5]. In addition, altered expression of the
imprinted IGF2 locus demonstrated the occurrence of genomic imprinting in humans, as well as
the consequences of its disruption during embryogenesis [6, 7]. Mutations in microRNA proces-
sors DGCR8,DROSHA, and DICER1 have underscored the importance of this pathway in devel-
opmental tumours [8–11], whereas mutations in SIX1 and SIX2 reflect their critical role in renal
development [9, 10, 12]. Characterisation of other recently reported recurrent somatic mutations
[9, 10, 13] will further clarify the mechanisms of nephrogenesis and neoplasia.
Familial and syndromic Wilms tumours have demonstrated the susceptibility of the devel-
oping kidney to germline variants of WT1 in children with genitourinary abnormalities [14],
BRCA2 and PALB2 in Fanconi anaemia patients [15, 16], GPC3 in Simpson-Golabi-Behmel
syndrome patients [17], DIS3L2 in Perlman syndrome [18], DICER1 in DICER1-related dis-
ease [19], BUB1B and TRIP13 in mosaic variegated aneuploidy (MVA) syndrome [20, 21], and
CTR9 [22], REST [23], PALB2, and CHEK2 [13] in non-syndromic Wilms tumour families. In
addition, linkage of familial Wilms tumours to 17q12-q21 [24] and 19q13.4 [25] implicate fur-
ther causative gene variants, although the evidence supporting the 19q13.4 locus was not con-
clusive [26].
Molecular characterisation of Wilms tumours has assisted in the stratification of tumours
into clinically relevant subgroups [27]. For example, children with tumours with diffuse ana-
plasia, associated with TP53 mutations [28], are recommended to receive more intense therapy
[27]. In addition, losses of chromosomal arms 1p or 16q are associated with poorer outcomes
[29] and augmented therapy has been recommended [27]. Conversely, small stage 1 tumours
with favourable histology in young children can be treated with less intense regimens [27].
Over-represented in this last group are a cluster of tumours (S1) described by Gadd and col-
leagues that do not harbour mutations in WT1, CTNNB1 or AMER1. These tumours usually
show retention of imprinting at IGF2, have a distinct gene expression pattern and have highly
differentiated monomorphic epithelial histology [30, 31].
Additional characterisation of Wilms tumour subtypes by molecular events and gene
expression should enable the refinement of clinically significant risk categories and enhance
therapeutic outcomes. Here we report the presence of truncating germline variants, somatic
mutation, and epigenetic silencing of TRIM28, in familial and non-familial cases of Wilms
tumour. Tumours with these alterations have the characteristic histology, gene expression and
outcome typical of the previously described S1 subtype [30].
Results
TRIM28mutations and methylation
We performed whole-exome sequencing on Wilms tumours and matched adjacent kidney
from 18 unrelated patients. Following processing of the sequence reads to variant calls, we first
TRIM28 mutations and Wilms tumour
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assessed the non-neoplastic kidney sequences for rare germline variants using a candidate
gene approach. Genes containing variants previously associated with Wilms tumour and genes
within regions of familial linkage, 17q12-q21 and 19q13.4, were included in this analysis.
One case (case 37, diagnosed at 39 months) showed a constitutional frameshift variant of
TRIM28 (NM_005762.2; c.525_526del) in the non-neoplastic kidney sample (Table 1, Fig 1A,
S1 Text). TRIM28, which encodes a transcriptional co-repressor, is located at 19q13.4 in the
proximity of a putative familial Wilms tumour locus [25]. Analysis of the sequence of the asso-
ciated tumour (37T) revealed loss of heterozygosity with retention of the variant allele (Fig 1A,
S1 Fig). Peripheral blood DNA from the patient’s sister, who was diagnosed with bilateral
Wilms tumours at 8 months of age (case 39), showed heterozygosity for the same 2-bp dele-
tion. DNA was then extracted from one of the paraffin-embedded tumours of case 39 revealing
loss of heterozygosity, with retention of the variant allele (Fig 1A). The same 2-bp deletion was
also present in peripheral blood from their asymptomatic mother thereby confirming maternal
transmission of the TRIM28 variant. Notably, the mother had no history of cancer.
Loss of function (LoF) variants of TRIM28 are exceedingly rare. To determine the preva-
lence of these events in the population, we interrogated the gnomAD database (http://gnomad.
broadinstitute.org/) which contains sequence data for more than 140,000 individuals. In total
four LoF variants were detected, two of which are described as low confidence variants. In
addition, the probability of LoF intolerance (pLI) for TRIM28 was 1.0 [ExAC database (http://
exac.broadinstitute.org/)], where pLI 0.9 indicates extreme LoF intolerance [32]. Further-
more, TRIM28 is constrained with respect to missense variation, having a constraint z score of
3.16 (ExAC database) indicating high intolerance to variation [32].
Tumour-kidney pairs were then analysed for acquired somatic pathogenic mutations (S1
Table). Among these 18 pairs, a heterozygous frameshift mutation in exon 13 of TRIM28
(c.1935delinsGA) was detected in a sporadic tumour (W117) (Table 1, Fig 1C), though a sec-
ond inactivating mutation or deletion could not be detected from the exome data. On inspec-
tion of exon read-depth it was noted that exon 1 was not represented in the aligned exome
sequences despite being included in the capture platform. In addition, exon 1 was intractable
to standard PCR approaches, presumably because of its high GC content (greater than 80%).
Table 1. Genetic, epigenetic and clinical features of monomorphic epithelial Wilms tumours.
Case number TRIM28 mutations Protein Sex Age of
onset
Features Outcome
37 c.525_526del in kidney with LOH in tumour p.
(Glu175Aspfs29)




39 c.525_526del in blood with LOH in tumour p.
(Glu175Aspfs29)
F 8 m Bilateral, monomorphic epithelial Alive at 20
years
Mother of 37 &
39
c.525_526del in blood p.
(Glu175Aspfs29)
F NA No childhood tumour Alive












M 8 m Stage 1, monomorphic epithelial Alive at 30
years
399 c.1746_1747delinsC with LOH in tumour p.
(Glu583Argfs93)
F 5 m Stage 1, monomorphic epithelial Alive at 29
years




† PLNR, perilobar nephrogenic rest
https://doi.org/10.1371/journal.pgen.1007399.t001
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To overcome this issue, W117 tumour DNA was bisulfite-treated to reduce the GC content
of the template, and Sanger sequence was produced for both treated DNA strands to determine
mutational status. No variants were detected, but extensive methylation across a 480-bp por-
tion of the CpG island that flanks exon 1 (S2 Fig) was discovered. Massively-parallel sequenc-
ing of bisulfite-converted DNA was then used to quantify methylation, revealing dense
methylation of all CpGs throughout the amplified 220-bp region in 39% of 1043 sequence
reads (Fig 1D; S3 Fig). In histologically normal adjacent kidney tissue, exon 1 methylation was
also detected in 1.2% of sequence reads whereas the exon 13 mutation was not detected, sug-
gesting low level mosaicism for TRIM28 hypermethylation (S4 Fig). In contrast, seven other
Wilms tumours, including five with similar histology, showed absence of methylation in this
region (S2 Fig). In addition, three normal kidney samples showed absence of methylated
TRIM28 alleles.
The observations of a heterozygous frameshift truncating mutation and a heterozygous
region of dense exon 1 CpG island methylation suggest that both alleles of TRIM28 have been
Fig 1. DNA sequence and methylation of TRIM28. (A) Family 1. 2-bp deletion (c.525_526del) in the blood of case 39 (39B), the
kidney of case 37 (37K) and the blood of their mother (37M) . The father (37F) was unaffected. The tumours from cases 37 and 39
(37T and 39T) showed loss of heterozygosity. (B) Family 2. Germline deletion/insertion (c.1746_1747delinsC) in blood DNA from
case 399 (399N) with loss of heterozygosity in tumours 399T and 249T. (C) Somatic deletion/insertion mutation (c.1935delinsGA)
in W117 tumour (W117T) and reference sequence in the adjacent kidney (W117K). (D) The proportion of methylated CpGs in
exon 1 of TRIM28 in W117T as measured by targeted bisulfite PCR. For each CpG site the black portion of the bar shows the
proportion of methylated reads.
https://doi.org/10.1371/journal.pgen.1007399.g001
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inactivated, although it cannot be formally excluded that the mutation and CpG island methyl-
ation affect the same allele.
Remarkably, the tumours from case 37, case 39 (sister of case 37) and case W117 shared the
same rare monomorphic epithelial histological pattern that occurs in approximately 5% of
Wilms tumours [30]. We, therefore, sought other tumours to determine whether loss of func-
tion of TRIM28 was a shared feature of monomorphic epithelial tumours.
A literature search to find other similar tumours identified a family involving an affected
mother and two children with monomorphic epithelial Wilms tumours (Table 1, cases 249
and 399) [33]. Targeted Sanger sequencing of all TRIM28 exons was achieved using tumour
DNA from both children and the blood DNA of case 399. A frameshift variant in exon 13
(c.1746_1747delinsC) was detected in the blood DNA of case 399 and in the tumours from the
children. Both tumours showed loss of the non-variant allele (Fig 1B). DNA from the mother’s
tumour or normal tissue was not available for sequencing.
We then identified a sporadic tumour with monomorphic epithelial histology among 92
Wilms tumours in the Sydney Children’s Tumour Bank Network (SCTBN). Targeted Sanger
sequencing of all TRIM28 exons of this tumour (SCTBN 88) did not identify any mutations
and exon 1 was unmethylated.
Loss of TRIM28 expression
Immunohistochemistry for TRIM28 protein was done for tumours 37T, 39T and W117 to
determine whether mutations in TRIM28 led to loss of protein expression. All three tumours
had a complete absence of TRIM28 protein in neoplastic cells (Fig 2A & 2B), although non-
Fig 2. TRIM28 immunohistochemistry. (A) Monomorphic epithelial Wilms tumours showing absence of TRIM28
expression in 37T and W117. (B) Absence of TRIM28 protein expression in tumour (T) but not in adjacent kidney (K)
in case 39. (C) Positive control showing TRIM28 expression in two representative Wilms tumours. Black line = 50 μM.
https://doi.org/10.1371/journal.pgen.1007399.g002
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tumour-derived endothelial cells and residual non-neoplastic kidney epithelial structures (K)
showed positivity. Nine other Wilms tumours were examined and all showed immunohisto-
chemical expression of TRIM28 in epithelial elements, examples of which are shown in Fig 2C.
Tumour SCTBN 88, which also showed monomorphic epithelial histology but no TRIM28
mutations, exhibited a normal pattern of TRIM28 expression by immunohistochemistry.
No other mutations detected in tumours with TRIM28 variants
Whole-exome sequencing of 37T and W117 revealed no somatic mutations of other genes
known to be mutated in Wilms tumour, including WT1, AMER1, CTNNB1,DROSHA,
DGCR8, SIX1, SIX2 and REST. Indeed, no additional missense or non-functional mutations
that passed standard filtering criteria were detectable in any other gene in these tumours. By
comparison, the 16 sequenced tumours without TRIM28 variants had a mean and median of 4
(range, 0–12) detected somatic variants (Fig 3).
Exome sequencing data were then used to detect copy number change and loss of heterozy-
gosity in the Wilms tumours (ADTEx, http://adtex.sourceforge.net). Tumour 37T showed
copy-neutral loss of heterozygosity at fourteen contiguous SNPs from chr19:59023166 (hg19)
to chr19:qter (chr19:59,118,983) without copy number variation, consistent with homozygos-
ity of the inherited variant (S5 Fig). The most distal heterozygosity on 19q was detected at
chr19:59,010,819 (rs2278497); therefore, the homozygous region includes the genes SLC27A5,
ZBTB45, TRIM28, MIR6807,CHMP2A, UBE2M, MZF1, and MZF1-AS1.
Apart from loss of heterozygosity within 19q13.43, tumour 37T showed no other chromo-
somal regions with copy number changes or loss of heterozygosity, above the baseline noise
level. The fractional length of aberrant copy number segments was quantified using segmenta-
tion data obtained with ADTEx, based on exome sequencing read depth. Tumour W117 also
showed no evidence of regional gains or losses or loss of heterozygosity throughout the
Fig 3. Somatic genetic changes in Wilms tumours. The left side shows the number of somatic non-synonymous and
truncating mutations for each tumour detected by MuTect2. The single somatic variant in W117 is the TRIM28
mutation. The right side shows the fractional length of aberrant copy number segments as determined by ADTEx.
https://doi.org/10.1371/journal.pgen.1007399.g003
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sequenced genome. In comparison, 12 of 16 other tumours without TRIM28 variants showed
extensive copy number change (Fig 3, S6 Fig). The fractional length of aberrant copy number
segments across the genome was 0.0003 in both 37T and W117 compared to a median of 0.06
for all tumours (Fig 3). The remarkable genomic simplicity of tumours 37T and W117 pro-
vides strong evidence that loss of TRIM28 is the sole driver of tumorigenesis in these cases.
Gene expression is consistent with that of the “S1” subgroup
The gene expression of 17 of these 18 Wilms tumours had previously been obtained using
Affymetrix Human Genome U133 Plus 2.0 Arrays [34]. Unsupervised hierarchical clustering
of tumour samples using 25,387 probes showed that the two TRIM28-mutated tumours for
which RNA was available (37T and W117) clustered together (Fig 4). In agreement with the
lack of TRIM28 protein, the expression of TRIM28 mRNA (probe 200990_at) in 37T and
Fig 4. Dendrogram from unsupervised hierarchical clustering of gene expression of 17 Wilms tumours. IGF2, refers to IGF2
status where blue = loss of imprinting, and red = loss of heterozygosity at IGF2. Rests refers to the presence of nephrogenic rests
(NR) were blue = intralobar NR, red perilobar NR and purple NR of unknown type. For each gene, red boxes indicate the
presence of mutation, whereas the grey box denotes gene deletion.
https://doi.org/10.1371/journal.pgen.1007399.g004
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W117 was substantially lower than in the other Wilms tumours, consistent with complete or
marked loss of expression (Fig 5).
We then compared the gene expression of 37T and W117 to that previously described for
the “S1” subgroup of Wilms tumours that have a distinctive monomorphic epithelial histology
[30]. First, we examined the gene expression data (GSE31403, Affymetrix Human Genome
U133A Array) from the publication of Gadd and colleagues that described 224 cases of favour-
able histology Wilms tumour [30]. To facilitate comparison with our tumour cohort, we iden-
tified and ranked the probes that showed the greatest difference in gene expression between S1
tumours (n = 11) and the S2-S5 tumours (n = 213). Using the data from Gadd and colleagues,
we identified 2476 and 2085 probes that showed higher and lower expression respectively in
the S1 tumours compared to the other tumours (analysed using limma software with an
adjusted p value cut-off of 0.05, Benjamini and Hochberg adjustment) [30]. Similarly, in the
TRIM28-mutant tumours (with less statistical power) 80 probes showed significantly higher
expression than non-mutant tumours, whereas 19 probes showed lower expression.
Of the probes that showed higher and lower expression in the TRIM28-mutant tumours, 51
(64%) and 15 (79%) were included in the differentially expressed probes from the data of Gadd
et al. [30]. The expression levels of the five most down-regulated and five most up-regulated
genes in the S1 compared to S2-S5 subgroups were examined in the TRIM28-mutant and non-
Fig 5. Comparison of gene expression between S1 and other Wilms tumours. The upper panels show the five most down-regulated and five
most up-regulated genes in the S1 subgroup (n = 11) compared to S2-S5 tumours (n = 213) in the study of Gadd et al. [30]. The lower panels show
expression of these genes in TRIM28-mutated tumours and 13 other tumours from this study. Red circles, S1 or TRIM28-mutated tumours. Blue
circles, favourable histology tumours. Note that two tumours with anaplastic histology, both of which had TP53 mutations, are not included to
maintain comparability with the favourable histology tumours reported by Gadd et al. [30].
https://doi.org/10.1371/journal.pgen.1007399.g005
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mutant tumours (Fig 5). The gene expression pattern is remarkably similar, suggesting that
TRIM28-mutant tumours 37T and W117 have the gene expression characteristics of the S1
subgroup. Indeed, the probe showing the most significant down regulation in S1 tumours
compared to the other tumours was probe 200990_at that targets TRIM28. Furthermore, in
eight of the 11 S1-subtype tumours the expression level of TRIM28 was distinctly lower than
that in all the 213 non-S1 tumours (Fig 5).
We then determined whether the differentially expressed genes (S1 vs S2-S5) elucidated the
processes of tumorigenesis or the tissue composition of the S1 tumours. We selected the 302
genes that showed at least two-fold higher expression in S1 compared to S2-S5 tumours and
an adjusted p< 0.01. We similarly selected 126 genes that had lower expression in S1 tumours.
Pathway and process enrichment analysis (http://metascape.org/) of the 302 over-expressed
and 126 under-expressed genes revealed enrichment of several unrelated biological processes
(S2 Table) from which convincing conclusions could not be drawn about the mechanisms of
tumorigenesis. Instead, we adopted a targeted approach by examining the expression of genes
shown to be involved in the different stages of nephrogenesis as documented by the Genito-
Urinary Development Molecular Anatomy Project [35]. Marker genes that are highly
expressed at each of several specific stages of kidney development were used to create “meta-
genes” that represent the expression pattern of a matrix of genes [36]. S1 tumours showed sig-
nificantly higher metagene scores for marker genes expressed during stage I / stage II nephron
development (including renal vesicle, comma-shaped body and s-shaped body development)
(S7 Fig). This association was largely driven by LHX1, CDH4, BMP2, POU3F3, CCND1, and
JAG1. In contrast, marker genes for stage III and IV nephron development, including renal
corpuscle and proximal tubule development were not associated with S1 tumours. Therefore,
the monomorphic epithelial elements of the S1 tumours are developmentally equivalent to
renal-vesicle-derived structures and not to mature epithelial elements.
Loss of TRIM28 did not affect genomic imprinting
TRIM28 has numerous roles as a transcriptional co-repressor, including involvement in the
establishment of imprinting [37, 38]. Therefore, we examined the allelic expression of H19 and
IGF2, genes known to be aberrantly imprinted in some Wilms tumours. IGF2 had normal
monoallelic expression in both tumours (37T and W117). In addition, H19 was monoallelically
expressed indicating retention of normal imprinting in tumour 37T. Together with the obser-
vations of retention of normal epigenetic status at IGF2/H19 in the previously published S1
subgroup [30], our observations suggest that the tumorigenic effects of TRIM28 variants are
not mediated through defects in the establishment or maintenance of imprinting at the IGF2/
H19 locus.
Lack of association with AMER1mutations
Since it has been reported that TRIM28 interacts with AMER1 (WTX) [39] we postulated that
tumours with mutations in AMER1 might share common features with TRIM28–mutated
tumours. Neither of the TRIM28-mutated tumours (37T and W117) had AMER1 mutations.
Following unsupervised clustering analysis of genome-wide gene expression (Fig 4) the
TRIM28 and AMER1-mutated tumours did not cluster together. Furthermore AMER1-
mutated tumours did not show the characteristic histological features of TRIM28-variant
tumours in our cohort, nor in that of Gadd and colleagues [30]. Therefore, there is no evidence
to suggest that TRIM28 and AMER1 variants are functionally equivalent in Wilms tumour, or
affect related pathways of tumorigenesis.
TRIM28 mutations and Wilms tumour
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Discussion
Here we report that mutations of TRIM28, a gene located in proximity of the candidate familial
Wilms tumour locus on 19q13.4, are present in the germline in families with Wilms tumours.
Remarkably, all four familial and one sporadic TRIM28-inactivated tumours had monomor-
phic epithelial morphology. Their morphology and gene expression pattern accord with those
reported for the “S1” subgroup of tumours that have an early age of onset and for which causa-
tive mutations have not yet been identified [13, 30]. Previous genome-wide sequencing studies
of Wilms tumours, which have targeted high risk blastemal tumours [10] and relapsed or ana-
plastic tumours [9, 13], did not reveal any germline TRIM28 variants in Wilms tumours
although a single somatic TRIM28 splice-site mutation has been detected in a TP53-mutated
tumour with diffuse anaplastic histology [13].
High levels of TRIM28 expression occurs in many tumour types [40], but loss of TRIM28
function has not previously been implicated in human cancer. The combination of frameshift
mutations and loss of heterozygosity or promoter methylation of the non-variant allele indi-
cates complete loss of TRIM28 function in the tumours, that was confirmed by immunohis-
tochemistry. Critically, TRIM28 appears to be essential for normal nephrogenesis, in that
silencing of Trim28 in cultured rat kidney rudiments resulted in branching arrest of the ure-
teric bud structures [41]. It is plausible that loss of ureteric bud development leads to a failure
to inhibit the growth of early epithelial structures from the undifferentiated metanephric mes-
enchyme. Current models of kidney development suggest, however, that differentiation and
growth of the earliest nephron-associated structures rely on inductive signals from the ureteric
bud tips, the absence of which is associated with failure of nephrogenesis [42, 43]. TRIM28 is
known to contribute to the regulation of a wide range of cellular processes including suppres-
sion of retrotransposons, regulation of gene expression through heterochromatisation, media-
tion of DNA damage response, stimulation of epithelial mesenchymal transition and
maintenance of stem cell pluripotency [40], highlighting multiple paths by which inactivation
of TRIM28 might induce Wilms tumorigenesis.
Wilms tumours are reported to have a low mutation burden. For example, Wegert and col-
leagues detected an average of 6 (0–15) non-synonymous somatic mutations, including mis-
sense, stop loss, stop gain, and splicing mutations in 58 blastemal type tumours by exome
sequencing [10]. Similarly, Walz and colleagues [9] reported an average of 11 high-quality
non-synonymous somatic mutations in favourable histology tumours (range 2–42). Here we
report a mean of four (range 0–12) high quality somatic variants per tumour, but unusually
the two TRIM28-mutant tumours analysed by exome sequencing revealed no additional muta-
tions. Using an exome-sequencing-based analysis, there were no meaningful structural
changes in these tumours except, in one case, copy-neutral loss of heterozygosity at 19q13.43
which encompasses TRIM28. The absence of other identifiable genomic changes in two
TRIM28-inactivated tumours suggests that loss of TRIM28 might be the sole driver of tumori-
genesis. As such these Wilms tumours could represent rare examples of the “two-hit” model of
Wilms tumorigenesis predicted by Knudson [44].
Interactions of TRIM28 with other known Wilms tumour-associated proteins raise the pos-
sibility of functional links to tumorigenesis. For example, TRIM28 has been identified as a
binding partner of REST [45], which is known to have germline or somatic mutations in
approximately 2% of Wilms tumours [23]; however, reported tumours with REST mutations
had more varied histology and older ages at diagnosis than our group of TRIM28-mutant
tumours. TRIM28 has also been reported to co-immunoprecipitate with AMER1, which is
mutated or deleted in 20–30% of Wilms tumours [46]. The expression patterns of AMER1 and
TRIM28 mutant tumours did not, however, cluster together, nor did they show similar
TRIM28 mutations and Wilms tumour
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histological features, suggesting that these two proteins contribute to different tumorigenic
pathways.
The clinical behaviour of all five TRIM28-variant tumours supports previous observations
that the monomorphic epithelial subtype of Wilms tumour is usually associated with excellent
prognosis and presentation with early stage disease [30].
However, not all monomorphic epithelial tumours have these features; those that do not,
tend to have presentation at later stages of diseases and at an older age [30]. In our study, one
monomorphic epithelial tumour had neither TRIM28 mutations nor loss of TRIM28 expres-
sion. We hypothesise that loss of TRIM28 expression or the presence of TRIM28 mutation, in
combination with monomorphic epithelial histology, can be used to identify the good progno-
sis S1 subtype of tumours. If this hypothesis is supported by future analysis of S1 tumours, it is
likely to provide a molecular basis for down-staging treatment in affected children, thereby
minimizing adverse effects of chemotherapy.
Methods
Ethics statement
Wilms tumours and normal samples were collected and analysed with approval from the
Health and Disability Ethics Committees, Ministry of Health, New Zealand (approval number
CTY/01/10/141). Informed verbal consent was given to the treating surgeon or oncologist
prior to tumour resection.
Exome sequencing, processing and analysis
Exome libraries were constructed and sequenced by the Kinghorn Centre for Clinical Geno-
mics (Garvan Institute of Medical Research, Sydney) using an Illumina HiSeq 2500 machine,
with prior enrichment using the SeqCap EZ Exome v3 (Roche) capture platform. Sequence
reads were paired end, with read lengths of 125 bases.
Processing and analysis of exome sequence data
Processing for alignment and standard variant calling was based on GATK Best Practice
Guidelines (https://software.broadinstitute.org/gatk/best-practices/). GATK version 3.5 was
used.
Alignment of reads
Paired-end reads in fastq format, derived from a single individual, were aligned to the refer-
ence sequence (GRCh37 assembly) using the Burrows-Wheeler Aligner v0.7.13 [47] with the
mem algorithm. Duplicate reads were identified using Picard MarkDuplicates. The data were
locally realigned around indels followed by Base Quality Score Recalibration to produce the
aligned files in bam format.
Identifying germline variants from non-tumour samples
A variant call of single nucleotide variants (SNVs) and short insertions/deletions (indels) were
generated for each sample using GATK HaplotypeCaller. Joint genotyping was done using
GATK GenotypeGVCFs to produce a standard variant calling dataset containing variant infor-
mation for all samples. This was followed by GATK LeftAlignAndTrimVariants and then Var-
iant Quality Score Recalibration was undertaken independently for SNPs and indels. To
facilitate the filtering of germline variants in the non-tumour samples, SnpEff version 4.2 [48]
was used to annotate with gene context information [49]. Annotation for population allele
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frequencies was added using GATK VariantAnnotator, with data from the 1000 Genomes
Project [50], and the Exome Aggregation Consortium [32].
Identifying somatic variants from tumour samples
Somatic SNVs and indels in tumour samples were called using the MuTect2 workflow (https://
software.broadinstitute.org/gatk/best-practices/mutect2.php). Non-tumour samples from 28
individuals, whose exome sequences were obtained using the same capture platform, was used
to create a panel of normals to exclude recurrent variants. dbSNP v137 was used as a “red” list,
and the COSMIC database v54 as a “white” list in the recommended workflow.
Regions of somatic copy number variation and loss of heterozygosity in
tumours
Copy number variants and loss of heterozygosity (LOH) were assessed in tumours using the
ADTEx (Aberration Detection in Tumour Exome) package v2.0 [51]. Initially, for each
tumour-normal pair, all biallelic variants that were heterozygous in the normal sample, with a
Genotype Quality greater than or equal to 14 and read depth between 11 and 1001 in both the
normal and the tumour sample, were extracted from the multi-sample standard variant call
file described above.
B-allele fractions were calculated and used in conjunction with the aligned bam files for the
tumour-normal pair and a bed file for the SeqCap EZ Exome v3 capture regions, as input for
the ADTEx package to identify regions of copy number variation (S6 Fig) and loss of heterozy-
gosity in each tumour. To provide a simple quantitative measure of the genomic regions
affected by copy number change, the segmentation data produced by ADTEx was used to esti-
mate the fraction of the genome affected. The total length of segments with copy gain or loss,
relative to the total length of segments reported for that tumour, was calculated as the frac-
tional copy number aberration score. The R package ‘ggplot2’[52] was used for visualisation of
regions of copy number variation and loss of heterozygosity (S5 and S6 Figs).
TRIM28 exon 1 bisulfite sequencing
Genomic DNA was bisulfite converted using EZ DNA Methylation kit (Zymo #D5002) and
PCR amplified using KAPA HiFi HotStart Uracil + polymerase (KAPA Biosystems KK2802)
and primers designed to a 253 bp region of TRIM28 exon 1 (GRCh37/hg19 chr19:59056298–
59056550) followed by a second round of PCR (10 cycles) to add indexed Illumina sequencing
adaptors (S3 Table). Products were then sequenced on an Illumina MiSeq sequencer (Reagent
kit V2, Nano). The methylation patterns of reads were visualised using BiQ Analyzer.
Expression analysis
Tumour mRNA expression data, generated using an Affymetrix HG-U133 Plus 2.0 GeneChip
Array, were available for 17 of the tumours in this study [34]. Expression data generated by
Gadd and colleagues using an Affymetrix HG-U133A GeneChip Array were downloaded
from GEO [53] (accession number GSE31403 [30]). Data were normalised using Robust
Multi-array Average algorithm implemented in the ‘affy’ R package [54]. Probe sets from both
datasets were filtered independently on inter-sample variance, and the 50% most variable
probes were retained. Further, probes with known cross-hybridisation issues were excluded
[55]. After filtering, 25387 probe sets were retained from this study’s data, while 9863 probe
sets remained from Gadd and colleague’s data.
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Hierarchical clustering of tumours was performed using Euclidean distance and average
linkage. Differential expression between S1 tumours and non-S1 tumours was detected using
the R package ’limma’, accounting for multiple comparisons through the BH method [56]. To
facilitate comparison between the two datasets, only probe sets present in both datasets that
mapped to known genes, were used.
For comparison of gene expression of S1-S5 tumours with kidney development marker
genes annotated in the GUDMAP database [35], the expression of each marker gene was
scaled to a mean of 0 and standard deviation of 1, a metagene value was determined (based on
first eigenvector from Singular Value Decomposition of the marker genes for that develop-
mental stage [36]) and the tumour subtypes were compared. The p values shown in S7 Fig are
not corrected for multiple comparisons.
Immunohistochemistry
TRIM28 immunohistochemistry was performed using an anti-KAP1 rabbit polyclonal anti-
body (Abcam ab10484) at a 1:2000 dilution, following antigen retrieval at pH 9.
Supporting information
S1 Text. Additional clinical details of the Wilms tumour cases.
(DOCX)
S1 Table. Missense and loss of function somatic variants identified in the Wilms tumours.
(XLSX)
S2 Table. Top 20 clusters with their representative enriched terms (one per cluster) associ-
ated with genes that had higher expression (n = 302) or lower expression (n = 126) in S1
than S2-S5 tumours (http://metascape.org/).
(XLSX)
S3 Table. PCR primers used in this study.
(XLSX)
S1 Fig. Pedigree description for cases with TRIM28 mutations. Known affection status is
annotated on each individual. A depiction of allele status is presented for each child for both
germline and tumour samples. A red bar represents a frameshifting mutation, while an orange
box represents hypermethylation. Square brackets indicate assumed status.  These tumours
showed loss of heterozygosity but it is unknown if the LOH is copy neutral or copy-loss in
these cases.  It cannot be formally excluded that the mutation and CpG island hypermethyla-
tion affected the same allele.
(TIFF)
S2 Fig. Bisulfite sequencing (reverse strand) of a portion of the CpG island flanking
TRIM28 exon 1. This shows equal peak heights for G and A nucleotides corresponding to an
equal proportion of C and T at multiple CpG sites, suggestive of hemimethylation of TRIM28
in Wilms tumour W117T. No evidence of methylation was detected in adjacent kidney tissue
(W117K), parental blood (W117M and W117F) and seven other Wilms tumours (two exam-
ples, 88T and 86T, are shown). The sequence traces are reverse sequences using primers com-
plementary to the bisulfite-converted lower strand (TRIM28_Exon1_BiSulf_Positive_3 & 4).
(TIFF)
S3 Fig. Methylation sequencing of TRIM28 in tumour W117. Each row shows one of 1043
alleles sequenced by MiSeq (GRCh37/hg19 chr19:59056298–59056550). Each column shows
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one of 23 CpG sites within exon 1 and intron 1 of TRIM28. 39.5% of sequence reads are
densely methylated (red), whereas 60% show unmethylation, consistent with allele-specific
methylation.
(TIFF)
S4 Fig. Methylation and genomic sequencing of TRIM28 in kidney adjacent to tumour
W117. Bisulfite sequencing of DNA extracted from the kidney adjacent to W117 (W117K-a)
revealed that 24 of 1757 (1.4%) sequences were densely methylated at TRIM28 exon 1. An
additional independent sample W117K-b of adjacent kidney was then assessed by microscopy
of H&E-stained frozen sections and found to be free of histological evidence of Wilms tumour.
DNA, extracted from an adjacent microtome section of this independent sample, was similarly
bisulfite converted and sequenced. Of 661 sequences, eight (1.2%) were densely methylated.
We also measured the proportion of alleles carrying the exon 13 c.1935delinsGA frameshift
mutation by using deep sequencing of the mutated exon. In the first sample 2 of 1077 (0.19%)
of alleles carried the mutation, whereas in the independent replicate 0 of 1212 did. These
results indicate that approximately 2.4% of cells carry a methylated TRIM28 allele in the
absence of the tumour-defining mutation suggesting that methylation within normal kidney
was the first TRIM28-inactivating event.
(TIFF)
S5 Fig. SNP allelic fraction (mirrored) at 19q13.43 showing the telomeric region of loss of
heterozygosity in tumour 37T.
(TIFF)
S6 Fig. Copy number variation of the 18 Wilms tumours compared to their paired normal
kidney samples, as determined by ADTex (Aberration Detection in Tumour Exome) pack-
age v2.0.
(TIFF)
S7 Fig. Analysis of expression of marker genes involved in different stages of nephrogen-
esis, as documented by the GenitoUrinary Development Molecular Anatomy Project, in
tumour subgroups from Gadd et al. [30].
(PDF)
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